Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 6,602 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multi Center Clear all
Completed Phase 3 Interventional

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

NCT00105287
View directory record Official record
Conditions
Pain, Cancer
Interventions
OraVescent fentanyl (OVF)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Cullman, Alabama • Anaheim, California • Corona, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 10, 2026, 2:38 PM EST
Not listed No phase listed Observational

Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis

NCT03113721
View directory record Official record
Conditions
Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
Interventions
Not listed
Lead sponsor
Axis Shield Diagnostics Ltd
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Philadelphia, Pennsylvania • York, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Nov 10, 2026, 2:38 PM EST
Terminated Phase 1 Interventional

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

NCT02323906
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CC-122, Sorafenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 10, 2026, 2:38 PM EST
Not yet recruiting No phase listed Observational Accepts healthy volunteers

The Systemic Nature of Severe Traumatic Brain Injury

NCT07679126
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

NCT06792539
View directory record Official record
Conditions
Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Interventions
Polymotion Hip Resurfacing (PHR) System
Device
Lead sponsor
JointMedica Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Enrolling by invitation Not applicable Interventional

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

NCT07148895
View directory record Official record
Conditions
Thyroglossal Duct Cysts
Interventions
Post-surgical drain, No post-surgical drain
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 17 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539
View directory record Official record
Conditions
Relapsed/Refractory Non-Hodgkin Lymphoma
Interventions
BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab, Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Active, not recruiting No phase listed Observational

Thoracostomy Tube Irrigation: a Multi-Center Trial

NCT05935267
View directory record Official record
Conditions
Thoracic Trauma
Interventions
thoracic irrigation
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 10, 2026, 2:38 PM EST
Terminated No phase listed Observational

Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

NCT03772145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Nov 10, 2026, 2:38 PM EST
Not listed Not applicable Interventional

A Comparison of Two Socket Sealing Collagen Matrices for Extraction Socket Management

NCT03003819
View directory record Official record
Conditions
Tooth Loss
Interventions
Control Collagen Wound Dressing, Test Collagen Matrix
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fenton, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Nov 10, 2026, 2:38 PM EST
Terminated Not applicable Interventional

Reduced Radiation Dose and IR-impact on Coronary Calcium Quantification

NCT04267094
View directory record Official record
Conditions
Atherosclerotic Plaque
Interventions
Iterative reconstruction at reduced radiation dose
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Nov 10, 2026, 2:38 PM EST
Terminated Phase 2 Interventional Results available

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

NCT00608894
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
LCP-Tacro (tacrolimus), Azathioprine
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 10, 2026, 2:38 PM EST
Completed No phase listed Observational Accepts healthy volunteers

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457
View directory record Official record
Conditions
22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
20,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
16
States / cities
San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

NCT04718181
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
risdiplam, omeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

NCT01337765
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions
BEZ235 + MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Nov 10, 2026, 2:38 PM EST
Terminated Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer

NCT00085631
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, hyperthermia treatment, brachytherapy, external beam radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Nov 10, 2026, 2:38 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

A Multi-centered Feedback and Education Intervention Designed to Reduce Inappropriate Transthoracic Echocardiograms

NCT02038101
View directory record Official record
Conditions
CARDIOVASCULAR DISEASES
Interventions
Education and Feedback
Behavioral
Lead sponsor
Women's College Hospital
Other
Eligibility
Not listed
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Nov 10, 2026, 2:38 PM EST
Recruiting Phase 1 Interventional

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
View directory record Official record
Conditions
ALS
Interventions
AMX0114, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

NCT00282256
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus modified release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Up to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Nov 10, 2026, 2:38 PM EST
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245
View directory record Official record
Conditions
Obesity and Overweight
Interventions
NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 10, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-751,871, docetaxel, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Nov 10, 2026, 2:38 PM EST
Active, not recruiting Phase 4 Interventional

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

NCT05610319
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 10, 2026, 2:38 PM EST